EBS Technologies GMBH is shattering the current paradigm that once a person loses sight it cannot be regained. Its NEXT WAVE repetitive retinofugal alternate current stimulation technology uses noninvasive electrical stimulation to reactivate networks of “silent neurons” in patients with ophthalmic diseases or who have lost vision following brain injury.

EBS Technologies GMBH is shattering the current paradigm that once a person loses sight it cannot be regained. Its NEXT WAVE repetitive retinofugal alternate current stimulation technology uses noninvasive electrical stimulation to reactivate networks of “silent neurons” in patients with ophthalmic diseases or who have lost vision following brain injury.

This Month's Profile Group, Antibodies Evolve, features profiles of GamaMabs, Numab, and Zebra Biologics. Plus these Start-Ups Across Health Care: CoolCore Biomedical Technologies, EBS Technologies, and Xeltis.

Neurostimulation technology is migrating into the ophthalmology field, and the implications could be significant for the millions of patients worldwide with degenerative eye diseases, including retinitis pigmentosa and age-related macular degeneration, as well as those with moderate-to-severe dry eye disease. Companies active in this space include Second Sight Medical Products, Retina Implant AG, Pixium Vision, Nano Retina, and many others.